Interstitial Lung Disease With Non–Vitamin K Oral Anticoagulants—A Clinical Concern?

Abstract

The landscape of atrial fibrillation (AF) management has changed considerably over the past decade, and the worldwide transition from warfarin to non-vitamin K oral anticoagulants (NOACs) has been almost fully achieved. 1 Notwithstanding the well-established advantages of NOACs over warfarin in AF, including a consistent and clinically relevant reduced risk of intracranial bleeding, postmarketing surveillance remains pivotal to characterize their comparative safety, especially with regard to rare but unpredictable nonbleeding adverse events.